Rafferty Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,484
| Closed | -$328K | – | 1105 |
|
|
2025
Q1 | $328K | Sell |
2,484
-1,746
| -41% | -$218K | ﹤0.01% | 939 |
|
|
2024
Q4 | $353K | Sell |
4,230
-1,590
| -27% | -$131K | ﹤0.01% | 992 |
|
|
2024
Q3 | $426K | Sell |
5,820
-131
| -2% | -$9.85K | ﹤0.01% | 979 |
|
|
2024
Q2 | $408K | Sell |
5,951
-1,566
| -21% | -$109K | ﹤0.01% | 998 |
|
|
2024
Q1 | $520K | Buy |
7,517
+725
| +11% | +$49.8K | ﹤0.01% | 965 |
|
|
2023
Q4 | $486K | Buy |
6,792
+526
| +8% | +$30.3K | ﹤0.01% | 987 |
|
|
2023
Q3 | $326K | Buy |
6,266
+1,410
| +29% | +$82.1K | ﹤0.01% | 1008 |
|
|
2023
Q2 | $307K | Buy |
4,856
+543
| +13% | +$33.8K | ﹤0.01% | 1037 |
|
|
2023
Q1 | $234K | Sell |
4,313
-154
| -3% | -$7.45K | ﹤0.01% | 1085 |
|
|
2022
Q4 | $236K | Sell |
4,467
-254
| -5% | -$12.7K | ﹤0.01% | 1053 |
|
|
2022
Q3 | $220K | Buy |
4,721
+251
| +6% | +$13.1K | ﹤0.01% | 1082 |
|
|
2022
Q2 | $255K | Sell |
4,470
-2,976
| -40% | -$169K | ﹤0.01% | 973 |
|
|
2022
Q1 | $456K | Sell |
7,446
-1,420
| -16% | -$73.7K | ﹤0.01% | 1030 |
|
|
2021
Q4 | $464K | Sell |
8,866
-683
| -7% | -$28.7K | ﹤0.01% | 1073 |
|
|
2021
Q3 | $356K | Buy |
+9,549
| New | +$332K | ﹤0.01% | 1107 |
|
|
2021
Q1 | – | Sell |
-11,666
| Closed | -$371K | – | 1172 |
|
|
2020
Q4 | $371K | Buy |
+11,666
| New | +$307K | ﹤0.01% | 757 |
|
|
2020
Q1 | – | Sell |
-6,476
| Closed | -$222K | – | 830 |
|
|
2019
Q4 | $222K | Sell |
6,476
-6,096
| -48% | -$73.2K | ﹤0.01% | 828 |
|
|
2019
Q3 | $94K | Buy |
+12,572
| New | +$121K | ﹤0.01% | 793 |
|
Other funds holding ITCI
Rafferty Asset Management's ITCI Position: Q2 2025 in Review
Rafferty Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,484 shares — an estimated $328K sold.
Rafferty Asset Management first reported a position in ITCI in Q3 2019 and held it in 18 quarters. The position peaked at $520K in Q1 2024. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Rafferty Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Rafferty Asset Management sold 2,484 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $328K.
- Rafferty Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 18 quarters.
- Rafferty Asset Management's Intra-Cellular Therapies Inc. position peaked at $520K in Q1 2024.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Rafferty Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.